BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23790315)

  • 1. The role of epigenetics in malignant pleural mesothelioma.
    Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
    Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
    Hamaidia M; Staumont B; Duysinx B; Louis R; Willems L
    Curr Top Med Chem; 2016; 16(7):777-87. PubMed ID: 26303419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Succinate Ether Derivative of Tocotrienol Enhances Dickkopf-1 Gene Expression through Epigenetic Alterations in Malignant Mesothelioma Cells.
    Sato A; Ueno H; Fusegi M; Kaneko S; Kohno K; Virgona N; Ando A; Sekine Y; Yano T
    Pharmacology; 2018; 102(1-2):26-36. PubMed ID: 29763912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
    J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
    Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
    Blum Y; Meiller C; Quetel L; Elarouci N; Ayadi M; Tashtanbaeva D; Armenoult L; Montagne F; Tranchant R; Renier A; de Koning L; Copin MC; Hofman P; Hofman V; Porte H; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; de Reyniès A; Jean D
    Nat Commun; 2019 Mar; 10(1):1333. PubMed ID: 30902996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Urso L; Cavallari I; Sharova E; Ciccarese F; Pasello G; Ciminale V
    Br J Cancer; 2020 Jan; 122(1):52-61. PubMed ID: 31819191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
    Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
    Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
    Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular heterogeneity of malignant pleural mesotheliomas].
    Tranchant R; Montagne F; Jaurand MC; Jean D
    Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    Baird AM; Finn SP; Gray SG; Sheils O
    J Thorac Oncol; 2021 Jan; 16(1):14-16. PubMed ID: 33384056
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
    Truini A; Coco S; Genova C; Mora M; Dal Bello MG; Vanni I; Alama A; Rijavec E; Barletta G; Biello F; Maggioni C; Grossi F
    Microrna; 2016; 5(1):12-18. PubMed ID: 26817512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.